Conditions: Advanced Gastric Cancer
Keywords: Gastric cancer capecitabine cisplatin sorafenib phase I phase II
Allocation: RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 22
Healthy volunteers: no

Brief summary:
There is strong scientific rationale for exploring the role of sorafenib with capecitabine and cisplatin (XP) in AGC. XP is a new standard of care in AGC and sorafenib is a novel signal transduction inhibitor that prevents tumor cell proliferation and angiogenesis through blockade of the Raf/MEK/ERK pathway at the level of Raf kinase and the receptor tyrosine kinases VEGF-R2 and PDGFR-beta.

Detailed description:

Arms:
arm 1: XP+sorafenib arm 2: XP

Interventions: intervention 1: Capecitabine, Cisplatin, Sorafenib
Intervention descriptions: intervention 1: Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks

Protocol document: